Felix Urra

Dr. Felix Urra

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Cell Reports
Verified
Journal Article
Open access
CCCesar Cardenas
Cesar Cardenas
MMMarioly Müller
Marioly Müller
AMAndrew McNeal
Andrew McNeal
ALAlenka Lovy
Alenka Lovy
FJFabian Jaňa
Fabian Jaňa
JFJ. Kevin Foskett
J. Kevin Foskett
In the absence of low-level ER-to-mitochondrial Ca(2+) transfer, ATP levels fall, and AMPK-dependent, mTOR-independent autophagy is induced as an essential survival mechanism in many cell types. Here, we demonstrate that tumorigenic cancer cell lines, transformed primary human fibroblasts, and tumors in vivo respond similarly but that autophagy is insufficient for survival, and cancer cells die while their normal counterparts are spared. Cancer cell death is due to compromised bioenergetics that can be rescued with metabolic substrates or nucleotides and caused by necrosis associated with mitotic catastrophe during their proliferation. Our findings reveal an unexpected dependency on constitutive Ca(2+) transfer to mitochondria for viability of tumorigenic cells and suggest that mitochondrial Ca(2+) addiction is a feature of cancer cells.

4 September 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FUFelix Urra
Felix Urra
FMFelipe Muñoz
Felipe Muñoz
MCMiguel Cordova-Delgado
Miguel Cordova-Delgado
MRMaría Paz Ramírez
María Paz Ramírez
BPBárbara Peña-Ahumada
Bárbara Peña-Ahumada
RARamiro Araya-Maturana
Ramiro Araya-Maturana
Highly malignant triple-negative breast cancer (TNBC) cells rely mostly on glycolysis to maintain cellular homeostasis; however, mitochondria are still required for migration and metastasis. Taking advantage of the metabolic flexibility of TNBC MDA-MB-231 cells to generate subpopulations with glycolytic or oxidative phenotypes, we screened phenolic compounds containing an ortho-carbonyl group with mitochondrial activity and identified a bromoalkyl-ester of hydroquinone named FR58P1a, as a mitochondrial metabolism-affecting compound that uncouples OXPHOS through a protonophoric mechanism. In contrast to well-known protonophore uncoupler FCCP, FR58P1a does not depolarize the plasma membrane and its effect on the mitochondrial membrane potential and bioenergetics is moderate suggesting a mild uncoupling of OXPHOS. FR58P1a activates AMPK in a Sirt1-dependent fashion. Although the activation of Sirt1/AMPK axis by FR58P1a has a cyto-protective role, selectively inhibits fibronectin-dependent adhesion and migration in TNBC cells but not in non-tumoral MCF10A cells by decreasing β1-integrin at the cell surface. Prolonged exposure to FR58P1a triggers a metabolic reprograming in TNBC cells characterized by down-regulation of OXPHOS-related genes that promote cell survival but comprise their ability to migrate. Taken together, our results show that TNBC cell migration is susceptible to mitochondrial alterations induced by small molecules as FR58P1a, which may have therapeutic implications.

14 July 2020 in Science Signaling
Verified
Journal Article
Closed access
PDF file
Cesar CardenasCesar Cardenas
Cesar Cardenas
ALAlenka Lovy
Alenka Lovy
ESEduardo Silva-Pavez
Eduardo Silva-Pavez
FUFelix Urra
Felix Urra
CMCraig Mizzoni
Craig Mizzoni
JFJ. Kevin Foskett
J. Kevin Foskett
Mitochondrial Ca 2+ influx promotes oxidative phosphorylation–independent pathways to enable cancer cell survival.

1 April 2016 in Cell Reports
Verified
Journal Article
Open access
CCCésar Cárdenas
César Cárdenas
MMMarioly Müller
Marioly Müller
AMAndrew McNeal
Andrew McNeal
ALAlenka Lovy
Alenka Lovy
FJFabian Jaňa
Fabian Jaňa
JFJ. Kevin Foskett
J. Kevin Foskett

11 February 2020 in Cells
Verified
Journal Article
Open access
PDF file
SFSebastián Fuentes-Retamal
Sebastián Fuentes-Retamal
CSCristian Sandoval-Acuña
Cristian Sandoval-Acuña
LPLiliana Peredo-Silva
Liliana Peredo-Silva
DGDaniela Guzmán-Rivera
Daniela Guzmán-Rivera
MPMario Pavani
Mario Pavani
JFJorge Ferreira
Jorge Ferreira
The mitochondrion has emerged as a promising therapeutic target for novel cancer treatments because of its essential role in tumorigenesis and resistance to chemotherapy. Previously, we described a natural compound, 10-((2,5-dihydroxybenzoyl)oxy)decyl) triphenylphosphonium bromide (GA-TPP+C10), with a hydroquinone scaffold that selectively targets the mitochondria of breast cancer (BC) cells by binding to the triphenylphosphonium group as a chemical chaperone; however, the mechanism of action remains unclear. In this work, we showed that GA-TPP+C10 causes time-dependent complex inhibition of the mitochondrial bioenergetics of BC cells, characterized by (1) an initial phase of mitochondrial uptake with an uncoupling effect of oxidative phosphorylation, as previously reported, (2) inhibition of Complex I-dependent respiration, and (3) a late phase of mitochondrial accumulation with inhibition of α-ketoglutarate dehydrogenase complex (αKGDHC) activity. These events led to cell cycle arrest in the G1 phase and cell death at 24 and 48 h of exposure, and the cells were rescued by the addition of the cell-penetrating metabolic intermediates l-aspartic acid β-methyl ester (mAsp) and dimethyl α-ketoglutarate (dm-KG). In addition, this unexpected blocking of mitochondrial function triggered metabolic remodeling toward glycolysis, AMPK activation, increased expression of proliferator-activated receptor gamma coactivator 1-alpha (pgc1α) and electron transport chain (ETC) component-related genes encoded by mitochondrial DNA and downregulation of the uncoupling proteins ucp3 and ucp4, suggesting an AMPK-dependent prosurvival adaptive response in cancer cells. Consistent with this finding, we showed that inhibition of mitochondrial translation with doxycycline, a broad-spectrum antibiotic that inhibits the 28 S subunit of the mitochondrial ribosome, in the presence of GA-TPP+C10 significantly reduces the mt-CO1 and VDAC protein levels and the FCCP-stimulated maximal electron flux and promotes selective and synergistic cytotoxic effects on BC cells at 24 h of treatment. Based on our results, we propose that this combined strategy based on blockage of the adaptive response induced by mitochondrial bioenergetic inhibition may have therapeutic relevance in BC.

1 September 2013 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
FUFelix Urra
Felix Urra
MCMiguel Cordova-Delgado
Miguel Cordova-Delgado
HPHernan Pessoa-Mahana
Hernan Pessoa-Mahana
OROney Ramírez-Rodríguez
Oney Ramírez-Rodríguez
BWBoris Weiss-Lopez
Boris Weiss-Lopez
RARamiro Araya-Maturana
Ramiro Araya-Maturana
A great number of alkaloids exhibit high potential in cancer research. Some of them are anticancer drugs with well-defined clinical uses, exerting their action on microtubules dynamics or DNA replication and topology. On the other hand, mitochondria have been recognized as an essential organelle in the establishment of tumor characteristics, especially the resistance to cell death, high proliferative capacity and adaptation to unfavorable cellular environment. Interestingly, many alkaloids exert their anticancer activities affecting selectively some functions of the tumor mitochondria by 1) modulating OXPHOS and ADP/ATP transport, 2) increasing ROS levels and mitochondrial potential dissipation by crosstalk between endoplasmic reticulum (ER) and mitochondria, 3) inducing mitochondria-dependent apoptosis and autophagy, 4) inhibiting mitochondrial metabolic pathways and 5) by alteration of the morphology and biogenesis of this organelle. These antecedents show the relevance of developing research about the effects of alkaloids on functions controlled by tumor mitochondria, offering an attractive target for the design of new alkaloid derivatives, considering organelle- specific delivery strategies. This review describes mitochondria as a central component in the anticancer action of a set of alkaloids, in a way to illustrate the importance of this organelle in medicinal chemistry.